


HCV-IN-31

Cat. No.:	HY-138305
CAS No.:	1998705-62-6
Molecular Formula:	C ₁₂ H ₁₇ N ₆ O ₃
Molecular Weight:	312.3
Target:	HCV
Pathway:	Anti-infection
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 60 mg/mL (192.12 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
			1 mM	3.2020 mL	16.0102 mL	32.0205 mL
			5 mM	0.6404 mL	3.2020 mL	6.4041 mL
			10 mM	0.3202 mL	1.6010 mL	3.2020 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (8.01 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.01 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (8.01 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	HCV-IN-31 (compound 4) is a HCV inhibitor, with an EC ₅₀ /EC ₉₅ of 15.7 μM for HCV replicon ^[1] .
IC ₅₀ & Target	EC ₅₀ /EC ₉₅ : 15.7 μM (HCV replicon) ^[1] .

REFERENCES

[1]. Jean-Pierre Sommadossi, et al. BETA-D-2-DEOXY-2-ALPHA-FLUORO-2- BETA-C-SUBSTITUTED-2-MODIFIED N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA